Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
|
Celldex Therapeutics, Inc. (CLDX)
|
Add to portfolio |
|
|
|
| Price: |
$39.18
| | Metrics |
| OS: |
47.3
|
k
| |
|
|
| Market cap: |
$1.85
|
M
| |
|
|
|
Net cash:
|
$253
|
M
| |
$5346.86
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 4.7 | 7.4 | 3.6 | 9.5 | 12.7 | 6.8 | 5.5 | 3.6 |
| Revenue growth | -37.3% | 107.6% | -62.5% | -25.2% | 87.8% | 23.8% | 52.8% | -12.8% |
| Cost of goods sold | 0.1 | 0.2 | 0.1 | 0.7 | 0.7 | 1.6 | 0.9 | 0.0 |
| Gross profit | 4.6 | 7.2 | 3.5 | 8.8 | 12.0 | 5.2 | 4.6 | 3.6 |
| Gross margin | 97.8% | 97.3% | 97.2% | 92.7% | 94.5% | 76.4% | 83.6% | 100.0% |
| Selling, general and administrative | | | | | | | | |
| Research and development | 53.3 | 42.5 | 42.7 | 66.4 | 96.2 | 102.7 | 100.2 | 104.4 |
| General and administrative | 20.5 | 14.5 | 15.4 | 19.3 | 25.0 | 36.0 | 33.8 | 20.6 |
| EBITA | -69.1 | -49.6 | -56.3 | -57.5 | -108.4 | -131.9 | -128.5 | -121.4 |
| EBITA margin | -1486.7% | -668.3% | -1576.4% | -602.9% | -850.9% | -1944.0% | -2345.4% | -3385.9% |
| Amortization of intangibles | | | | 0.2 | 0.9 | 1.0 | 1.0 | 1.0 |
| EBIT | -69.1 | -49.6 | -56.3 | -57.7 | -109.3 | -132.9 | -129.5 | -122.4 |
| EBIT margin | -1486.7% | -668.3% | -1576.4% | -605.2% | -857.9% | -1958.7% | -2363.9% | -3414.1% |
| Pre-tax income | -70.7 | -60.9 | -50.9 | -151.9 | -117.3 | -128.5 | -127.2 | -118.1 |
| Income taxes | -0.2 | -1.2 | 0.0 | -0.8 | -24.3 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.3% | 1.9% | 0.0% | 0.5% | 20.7% | 0.0% | 0.0% | 0.0% |
| Net income | -70.5 | -59.8 | -50.9 | -151.2 | -93.0 | -128.5 | -127.2 | -118.1 |
| Net margin | -1516.0% | -805.9% | -1424.0% | -1585.1% | -730.1% | -1894.0% | -2321.1% | -3292.8% |
| |
| Diluted EPS | ($1.64) | ($2.02) | ($3.51) | ($14.48) | ($10.86) | ($18.99) | ($1.31) | ($1.32) |
| Shares outstanding (diluted) | 42.9 | 29.6 | 14.5 | 10.4 | 8.6 | 6.8 | 97.1 | 89.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|